Abstract P5-02-20: Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer

作者
Jacqueline J. Tao,Saumya Dushyant Sisoudiya,Smruthy Sivakumar,Ethan S. Sokol,Neil Vasan
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (12_Supplement): P5-02
标识
DOI:10.1158/1557-3265.sabcs24-p5-02-20
摘要

Abstract Background: The AKT inhibitor capivasertib was recently approved in the 2L+ setting for patients (pts) with hormone receptor-positive metastatic breast cancer with alterations in PIK3CA, AKT1, and/or PTEN. There is a need to further characterize the landscape of PIK3CA, AKT1, and PTEN mutations in breast cancer and their functions, to improve our understanding and therapeutic targeting of PI3K-driven breast cancer. Methods: 51,767 pts with breast cancer who underwent tumor sequencing using FoundationOne®CDx or FoundationOne® were included in this analysis. We assessed the frequency, type, and pathogenicity of genomic alterations found in PIK3CA, PTEN, and AKT1 overall and stratified by receptor subtype, patient ancestry, and sample type. Co-occurrence with other pathogenic variants was explored using a Fisher’s exact test with a FDR correction. We correlated PTEN mutations with functional data from deep mutational scanning. Results: The most frequently altered PI3K-pathway gene was PIK3CA (37.4%, 19,384/51,767), followed by PTEN (13.5%) then AKT1 (5.4%), including both pathogenic and VUS alterations in all genes. Among 1,024 distinct PIK3CA alterations identified, 690 (67.4%) were missense mutations. The most common missense mutations were H1047R (35.6% of PIK3CA-altered cases), E545K (19.7%), and E542K (11.7%). Among 288 AKT1 alterations identified, 205 (71.2%) were missense mutations. The most common missense mutation was E17K (69.7% of AKT1-altered cases) followed by gene amplification (14.0%). The most common alteration among patients bearing PTEN alterations was gene deletion (37.3% of PTEN-altered cases). Among 1,723 distinct PTEN alterations identified, 721 (41.9%) were frameshift mutations, 494 (28.7%) were missense mutations, and 246 (14.3%) were splice site mutations. To determine function, PTEN mutations were correlated with existing PTEN deep mutational scanning datasets; these data will be presented. PIK3CA pathogenic alterations were more prevalent in estrogen receptor (ER)+/HER2- and HER2+ cases (40.3% and 37.6% of cases) versus triple negative breast cancer (TNBC; 20.9%), consistent with previously described data. Among all pathogenic PIK3CA alterations, those outside the 542, 545, and 1047 codons were more common in TNBC (42%) compared to ER+/HER2- or HER2+ (33%, p=0.002 and 33%, p=0.002). AKT1 mutations were more prevalent in ER+/HER2- disease (6.0%) than HER2+ or TNBC (1.7%, p=4.7x10^-20 and 3.0%, p=3.5x10^-5). In contrast, PTEN alterations were more commonly found in TNBC (17.9%) than in ER+/HER2- and HER2+ cases (11.3%, p=1.8x10^-8 and 3.9%, p=2x10^-57). PIK3CA alterations were enriched in metastases compared to local tumors (39.6% vs 33.2%, p=6x10^-41) and were less prevalent in African American pts than other groups (27.1% v 38.6% in Europeans, p=9.6x10^-81), while PTEN and AKT alterations were similar across ancestries. PIK3CA, AKT1, and PTEN pathogenic alterations are all mutually exclusive to each other. Statistically significant co-occurring mutations included PIK3CA with CDH1, MAP3K1, SOX2, TBX3, and PRKCI; PTEN with FAS, TP53, and RB1; and AKT1 with NF1. Conclusions: Here we describe the clinicogenomic landscape of PIK3CA, AKT1, and PTEN alterations in a large breast cancer cohort. Our results corroborate previously reported findings that PIK3CA alterations are present in around 40% of ER+/HER2- breast cancer and concentrated in 3 hotspots. However, one-third of patients have variants beyond E542, E545, and H1047 with less certainty about targetability. The preponderance of rare PIK3CA mutations and co-occurrences between PIK3CA, AKT1, and PTEN with genes outside the PI3K pathway merits functional investigation. Citation Format: Jacqueline Tao, Saumya Sisoudiya, Smruthy Sivakumar, Ethan Sokol, Neil Vasan. Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-02-20.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
秋风的应助被神龙大冲冠军采纳,获得20
1秒前
zn完成签到,获得积分10
2秒前
芯子发布了新的文献求助10
2秒前
chan完成签到,获得积分10
3秒前
Akim的应助被钉钉采纳,获得10
3秒前
聪明的归尘完成签到,获得积分10
3秒前
coozrasimon发布了新的文献求助10
4秒前
一色彩羽完成签到 ,获得积分10
5秒前
慕容平安完成签到,获得积分10
6秒前
yzy发布了新的文献求助10
6秒前
lydia完成签到,获得积分10
6秒前
6秒前
zhangxu完成签到,获得积分10
6秒前
Leolr10完成签到,获得积分20
7秒前
热辣卤肉发布了新的文献求助10
8秒前
8秒前
CodeCraft的应助被shan采纳,获得10
9秒前
张伟完成签到,获得积分10
9秒前
完美世界的应助被武淑晴采纳,获得10
10秒前
一口一完成签到,获得积分10
10秒前
10秒前
acadedog完成签到,获得积分10
10秒前
xooo完成签到 ,获得积分10
11秒前
睡不醒发布了新的文献求助10
11秒前
12秒前
12秒前
hxn发布了新的文献求助10
12秒前
fengfeng完成签到 ,获得积分10
13秒前
13秒前
14秒前
哟邮票发布了新的文献求助10
15秒前
Jm完成签到,获得积分10
15秒前
传奇3的应助被温凉采纳,获得10
16秒前
16秒前
雪白冷荷完成签到,获得积分10
17秒前
17秒前
滴迪氐媂完成签到 ,获得积分10
18秒前
十三发布了新的文献求助10
18秒前
Yuan88发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211